Eli Lilly Shares Poised for Potential Rebound Amid Key Developments

Eli Lilly and Company is approaching a pivotal period marked by two significant catalysts. While the pharmaceutical giant’s stock has faced considerable pressure this year, upcoming clinical data and a major regulatory shift could reshape its investment narrative in the coming weeks.

Upcoming Earnings and Analyst Sentiment

The company is scheduled to release its quarterly financial results on April 30th. This report will follow closely on the heels of an anticipated FDA decision in April regarding Orforglipron, Lilly’s daily oral obesity treatment. These events arrive at a time when investor sentiment has wavered, with shares declining approximately 16% year-to-date, underperforming the broader S&P 500 index. Concerns persist over whether demand for GLP-1 class medications can meet lofty market expectations.

Despite the share price weakness, major financial institutions maintain a constructive outlook. Morgan Stanley reaffirmed an Overweight rating with a price target of $1,313, suggesting potential upside of about 6% to its 2026 revenue estimates for Mounjaro and Zepbound. Similarly, Jefferies continues to recommend buying the stock, with a $1,300 price target.

Compelling Combination Therapy Data

Recent clinical findings presented at the American Academy of Dermatology’s annual meeting have strengthened Lilly’s portfolio strategy. The TOGETHER-PsA study evaluated the simultaneous use of Taltz (Ixekizumab) and Zepbound (Tirzepatide) in patients with active psoriatic arthritis who are also overweight—a relevant population given that an estimated 65% of U.S. patients with this condition live with obesity.

The data proved robust. The primary endpoint, achieving an ACR50 response combined with at least 10% weight reduction, was met by 31.7% of patients in the combination therapy group, compared to just 0.8% for those on Taltz alone. For a key secondary endpoint, the combination showed an ACR50 rate of 33.5%, versus 20.4% for Taltz monotherapy. Furthermore, 84.5% of combination therapy patients achieved weight loss of at least 10%, compared to 4.5% in the control group.

Should investors sell immediately? Or is it worth buying Eli Lilly?

This research holds strategic importance for Lilly as Taltz is expected to lose patent protection in the foreseeable future. Establishing a combination protocol with the newer Zepbound could help mitigate the anticipated revenue decline.

Structural Demand Catalyst from Medicare

A parallel and potentially transformative demand driver is taking shape. Beginning April 1, 2026, Medicare beneficiaries are expected to gain access to Zepbound for a maximum cost of $50 per month, contingent upon FDA approval for relevant indications. CEO Dave Ricks estimates that between 20 and 30 million Medicare enrollees could be eligible for GLP-1-based treatments.

This timeline aligns with Lilly’s planned launch of Orforglipron in the second quarter of 2026. Ricks anticipates that treatment volumes will accelerate in the latter half of that year once Medicare coverage is fully implemented, even accounting for an initial price reduction resulting from agreements with the U.S. government.

The convergence of these clinical and commercial milestones sets the stage for a critical phase. The coming weeks will reveal whether demonstrated therapeutic benefits and the prospect of expanded insurance coverage can shift investor perspective.